HYPERKALEMIA AFTER HOSPITALIZATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: FINDINGS FROM THE ASTRONAUT TRIAL

Hyperkalemia (hyperK+) may limit the optimal use of RAAS inhibitors and represents an emerging target for therapy. We report rates, temporal patterns, and key predictors of hyperK+ after hospitalization for HFrEF. The ASTRONAUT trial randomized 1,639 HFrEF patients with EF≤ 40% and elevated NP